Evidence map›Paper›PMID 26071399›Full record

SynthesisCarcinogenesis2015

Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer.

Hamed Khalili, Jian Gong, Hermann Brenner, Thomas R Austin, Carolyn M Hutter, Yoshifumi Baba, John A Baron, Sonja I Berndt, Stéphane Bézieau, Bette Caan and 52 more

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. The Mechanism ofThe Malaysian journal of medical sciences : MJMS · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Mapping hyper-susceptibility to colitis-associated colorectal cancer in FVB/NJ mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

62 authors at 20 institutions in 7 countries.

Hamed KhaliliGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.
Jian GongPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany, German Cancer Cosortium (DKTK), Heidelberg, Germany.
Thomas R AustinWhitman College, Walla Walla, WA, USA.
Carolyn M HutterDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Yoshifumi BabaDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
John A BaronDepartment of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Stéphane BézieauCHU Nantes, Service de Génétique Médicale, Nantes, France.
Bette CaanDivision of Hematology, Faculty of Medicine, The University of Ottawa, Ottawa, ON, Canada.
Peter T CampbellEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Constance ChenProgram in Molecular and Genetic Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shuo JiaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
David V ContiKeck School of Medicine, University of Southern California, Los Angles, CA, USA.
David DugganSystems Imagination, Computational Biology, Pheonix, AZ, USA.
Charles S FuchsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, Department of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA.
Manish GalaGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.
Steven GallingerDepartment of Surgery, University Health Network Toronto General Hospital, Toronto, ON, Canada.
Robert W HaileStanford Cancer Institute, Palo Alto, CA, USA.
Tabitha A HarrisonPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Richard HayesDivision of Epidemiology, New York University School of Medicine, New York, NY, USA.
Aditi HazraDepartment of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA.
Brian HendersonKeck School of Medicine, University of Southern California, Los Angles, CA, USA.
Chris HaimanKeck School of Medicine, University of Southern California, Los Angles, CA, USA.
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
John L HopperMelbourne School of Population Health, The University of Melbourne, Melbourne, Australia.
Mark A JenkinsDivision of Epidemiology, New York University School of Medicine, New York, NY, USA.
Laurence N KolonelEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Sébastien KüryCHU Nantes, Service de Génétique Médicale, Nantes, France.
Andrea LaCroixPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Loic Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Mathieu LemireOntario Institute for Cancer Research, Toronto, ON, Canada.
Noralane M LindorDepartment of Health Science Services, Mayo Clinic, Scottsdale, AZ, USA.
Jing MaDepartment of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA.
JoAnn E MansonDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Teppei MorikawaDepartment of Pathology, The University of Tokyo Hospital, Tokyo, Japan.
Hongmei NanDepartment of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Reiko NishiharaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
John D PotterPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Department of Epidemiology, University of Washington, Seattle, WA, USA, Center for Public Health Research, Massey University, Wellington, New Zealand.
Conghui QuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Fredrick R SchumacherKeck School of Medicine, University of Southern California, Los Angles, CA, USA.
Daniela SeminaraDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Darin TavernaSystems Imagination, Computational Biology, Pheonix, AZ, USA.
Stephen ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jean Wactawski-WendeDepartment of Social and Preventive Medicine, University of Buffalo, Buffalo, NY, USA.
Emily WhitePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kana WuDepartment of Nutrition, Harvard School of Public Health, Boston, MA, USA.
Brent W ZankeClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, USA.
Graham CaseyKeck School of Medicine, University of Southern California, Los Angles, CA, USA.
Thomas J HudsonOntario Institute for Cancer Research, Toronto, ON, Canada, Department of Medical Biophysics, University of Toronto, Toronto, ON, USA.
Peter KraftProgram in Molecular and Genetic Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, Department of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Martha L SlatteryDepartment of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Shuji OginoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA achan@mgh.harvard.edu shuji_ogino@dfci.harvard.edu.
Andrew T ChanGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA, Department of Epidemiology, Indiana University School of Public Health, Indianapolis, IN, USA, achan@mgh.harvard.edu shuji_ogino@dfci.harvard.edu.
GECCO and CCFR
Fred Hutch Cancer Center · USUniversity of Southern California · USIndiana University – Purdue University Indianapolis · USDana-Farber Cancer Institute · USHarvard University · USNational Cancer Institute · USBrigham and Women's Hospital · USGénétique Médicale & Génomique Fonctionelle · FRHeidelberg University · DEMassachusetts General Hospital · USMayo Clinic in Arizona · USNew York University · USOntario Institute for Cancer Research · CAAmerican Cancer Society · USCancer Center of Hawaii · USDivision of Cancer Epidemiology and GeneticsGerman Cancer Research Center · DEKumamoto University · JPPalo Alto Institute · USThe University of Melbourne · AU

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Intramural NIH HHS Z01 CP010200NCATS NIH HHS UL1 TR001108NCI NIH HHS CA42182NCI NIH HHS CA61757NCI NIH HHS K05 CA154337NCI NIH HHS K07 CA148894NCI NIH HHS K07 CA190673NCI NIH HHS P01 CA87969NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA071789NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA060987NCI NIH HHS R01 CA061757NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA143237NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA48998NCI NIH HHS R01 CA60987NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA074799NCI NIH HHS U01 CA074800NCI NIH HHS U01 CA074806NCI NIH HHS U01 CA097735NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA164973NCI NIH HHS U01/U24 CA074783NCI NIH HHS U01/U24 CA074794NCI NIH HHS U01/U24 CA074799NCI NIH HHS U01/U24 CA074800NCI NIH HHS U01/U24 CA074806NCI NIH HHS U01/U24 CA097735NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS U24 CA074799NCI NIH HHS U24 CA074800NCI NIH HHS U24 CA074806NCI NIH HHS U24 CA097735NCI NIH HHS UM1 CA167551NCI NIH HHS UM1 CA 167552NCI NIH HHS UM1 CA186107NCI NIH HHS Z01 CP 010200NHGRI NIH HHS U01 HG 004438NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CNIDDK NIH HHS K23 DK099681NIDDK NIH HHS K23 DK103119NIDDK NIH HHS K24 [DK]098311NIDDK NIH HHS P30 DK043351NIH HHS S10 OD020069WHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

Although genome-wide association studies (GWAS) have separately identified many genetic susceptibility loci for ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC), there has been no large-scale examination for pleiotropy, or shared genetic susceptibility, for these conditions. We used logistic regression modeling to examine the associations of 181 UC and CD susceptibility variants previously identified by GWAS with risk of CRC using data from the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry. We also examined associations of significant variants with clinical and molecular characteristics in a subset of the studies. Among 11794 CRC cases and 14190 controls, rs11676348, the susceptibility single nucleotide polymorphism (SNP) for UC, was significantly associated with reduced risk of CRC (P = 7E-05). The multivariate-adjusted odds ratio of CRC with each copy of the T allele was 0.93 (95% CI 0.89-0.96). The association of the SNP with risk of CRC differed according to mucinous histological features (P heterogeneity = 0.008). In addition, the (T) allele was associated with lower risk of tumors with Crohn's-like reaction but not tumors without such immune infiltrate (P heterogeneity = 0.02) and microsatellite instability-high (MSI-high) but not microsatellite stable or MSI-low tumors (P heterogeneity = 0.03). The minor allele (T) in SNP rs11676348, located downstream from CXCR2 that has been implicated in CRC progression, is associated with a lower risk of CRC, particularly tumors with a mucinous component, Crohn's-like reaction and MSI-high. Our findings offer the promise of risk stratification of inflammatory bowel disease patients for complications such as CRC.

Indexed as

Microsatellite InstabilityColitis, UlcerativeColorectal NeoplasmsCrohn DiseaseGene FrequencyGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMicrosatellite RepeatsPolymorphism, Single NucleotideRiskWhite People

Identifiers

PMID26071399
PMCPMC4573660
OpenAlexW2114509044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.